Cartei F, Danesi R, Ducci F, Fatigante L, Caciagli P G, Tacca M, Laddaga M
Cattedra di Radioterapia, Scuola Supriore di Studi Universitari e di Perfezionamento S Anna, Pisa, Italy.
Acta Oncol. 1994;33(8):969-73. doi: 10.3109/02841869409098465.
The pharmacokinetic properties of nicotinamide and its tolerance were studied in seven patients affected by glioblastoma multiforme and treated with two fractions per day of radiation therapy. Nicotinamide was given orally at two daily doses of 4 g and then 2 g separated by a 6-h-interval. The treatment was well tolerated in almost all patients and had no effect on blood pressure, cardiac rhythm or body temperature. Pharmacokinetic analysis showed peak plasma levels (Cmax) above 100 mg/l 45 minutes after the administration of both doses. This was followed by a biexponential decay of plasma concentrations with a thermal half life of 9.4h. Tumours were irradiated 1 hour after each drug dose to match with drug Cmax in plasma, and although it is too early to evaluate the tumour response, the drug levels achieved should be sufficient to improve radiation therapy.
对7例多形性胶质母细胞瘤患者进行了烟酰胺的药代动力学特性及其耐受性研究，这些患者接受每天两次的放射治疗。烟酰胺口服给药，每日两次，剂量分别为4g，然后2g，间隔6小时。几乎所有患者对该治疗耐受性良好，且对血压、心律或体温均无影响。药代动力学分析显示，两次给药后45分钟血浆峰值水平（Cmax）均高于100mg/l。随后血浆浓度呈双指数衰减，热半衰期为9.4小时。每次给药后1小时对肿瘤进行照射，以使血浆中的药物Cmax与之匹配，虽然评估肿瘤反应为时尚早，但所达到的药物水平应足以改善放射治疗。
